Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.5.0.2
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current assets: (Note 1):    
Cash and cash equivalents $ 2,447,320 $ 2,012,283
Short-term investments 12,416,087 14,147,991
Accounts receivable, net 21,508
Inventories (Note 2) 412,106
Prepaid expenses and other current assets 322,867 251,778
Total current assets 15,619,888 16,412,052
Property and equipment, net (Note 3) 95,387 1,954,496
Intangible rights acquired (Note 2) 2,291,966
Long-term investments (Note 1) 972,000
Other long term assets, net (Notes 1 and 4) 1,315,556 1,523,649
Total assets 19,322,797 20,862,197
Current liabilities:    
Accounts payable 297,044 701,064
Accrued compensation 329,098 449,873
Accrued expenses 233,506 241,882
Notes and other obligations, current portion (Note 5) 222,135 301,250
Deferred revenue, current portion (Note 8) 96,698 96,698
Total current liabilities 1,178,481 1,790,767
Notes and other obligations, less current portion (Note 5) 1,838,779
Deferred revenue, less current portion (Note 8) 1,089,490 1,162,015
Total liabilities 2,267,971 4,791,561
Commitments and contingencies (Notes 8 and 9)
Venaxis' stockholders' equity:    
Common stock, no par value, 60,000,000 shares authorized; 4,503,971 and 3,876,961 shares issued and outstanding 124,598,545 121,653,075
Accumulated deficit (107,568,735) (105,582,439)
Total Venaxis stockholders' equity 17,029,810 16,070,636
Non-controlling interest 25,016
Total equity 17,054,826 16,070,636
Total liabilities and stockholders' equity $ 19,322,797 $ 20,862,197